ENGLEWOOD CLIFFS, NJ, May 09, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 11,622,948 titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress…

Source

Previous articlePsychedelic Bulletin #137: Oregon Approves First Psilocybin Service Centre; AMA Approves Psychedelic CPT Code; MindMed Seeks to Fend Off Proxy Contest
Next articlePT409 – Pathology, the DSM, and the Ontological Shock of Psychedelic Experiences